Affiliation:
1. Department of Pediatric Neurology, Selcuk University Meram Medical Medical Faculty, Konya, Turkey,
2. Department of Pediatric Neurology, Gazi University Medical Faculty, Ankara, Turkey
3. Department of Pediatric Neurology, Mersin University Medical Faculty, Mersin, Turkey
4. Department of Pediatric Endocrinology, Gazi University Medical Faculty, Ankara, Turkey
Abstract
Weight gain is a common side effect of valproate treatment. The potential mechanisms of valproate-associated weight gain are not yet clear. Decreased blood glucose level, impairment of β-oxidation of fatty acids, and increased insulin levels are some of the possible mechanisms. The aim of the present study is to evaluate the role of insulin, leptin, and neuropeptide Y in valproate-related weight gain in epileptic children. In 20 epileptic children treated with valproate before treatment and after a follow-up period of 3 and 6 months, body mass index and fasting insulin glucose ratio were calculated and serum glucose, insulin, cortisol, leptin, and neuropeptide Y levels were measured. At the end of 3 months, the mean body mass index values and the mean serum insulin, fasting insulin glucose ratio, and neuropeptide Y levels increased, whereas the serum glucose levels decreased. After 6 months of treatment, the mean serum cortisol and leptin levels were high, in addition to the body mass index, neuropeptide Y, and fasting insulin glucose ratio. These results suggest that weight gain during valproate treatment might be related to low glucose and high insulin, cortisol, leptin, and neuropeptide Y levels. ( J Child Neurol 2005;20:848—851).
Subject
Neurology (clinical),Pediatrics, Perinatology and Child Health
Cited by
61 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献